Ulcerative colitis currently exhibits a strong pipeline with approximately 89 drug candidates by P&S Market Research.
The ulcerative colitis pipeline analysis report covers approximately 89 drug candidates in different stages of development.
Ulcerative colitis is a chronic inflammatory disease, which basically affect colonic mucosa. The main identified symptoms of the disease are bloody diarrhea, abdominal cramps and fatigue.
Some of the other symptoms include, fever, vomiting, anorexia, abdominal distension and bloating.
Browse Detailed Report Description at: https://www.psmarketresearch.com/market-analysis/ulcerative-colitis-pipeline-analysis
The research found that different companies are engaged in the collaboration for ulcerative colitis. In June, 2015 Lycera Corp. and Celgene Corporation collaborated for the development of Lycera Corp.
drug candidate for the treatment of ulcerative colitis. Celgene obtained the exclusive right to acquire Lycera upon conclusion of the option period or achievement by Lycera of pre-specified clinical milestones.
During the option period, Lycera retained full control of its research and development programs.
Explore Report Sample at: www.psmarketresearch.com/market-an…is/report-sample
Some of the key players developing ulcerative colitis therapeutics include EA Pharma Co., Ltd., Celgene Corporation, InDex Pharmaceuticals AB and others.
Category: Market Research Publishers and RetailersCompany profile: PS Market Research is a global market research and consulting company. We provide market research reports, industry reports, business intelligence and research based consulting services across a range of industries. With the help of our professional corporate relations with various companies, our market research offers the most accurate market forecasting. Our analysts and consultants interact with leading companies of the concerned domain to substantiate every single data presented in our pub ...
For more information: